spec sheet6 rows
Nelivaptan chased a genuinely novel idea in psychiatry, blocking the vasopressin V1b receptor instead of tuning serotonin or GABA, on the logic that vasopressin drives the body's stress and HPA-axis response and that dialing it down might relieve anxiety and depression without the sedation or dependence baggage of benzodiazepines. Sanofi-Aventis ran it through four large, well-controlled Phase II trials for major depressive disorder and generalized anxiety disorder between 2006 and 2008, comparing it against escitalopram and paroxetine. The results were unambiguous in the wrong direction; nelivaptan showed no meaningful benefit over placebo in GAD and only inconsistent signals in depression, closing the book on vasopressin antagonism as an anxiety treatment for over a decade.
- strong anxiolytic- and antidepressant-like effects in preclinical rodent models of stress
- no dependence or sedation liability typical of GABAergic anxiolytics
- Nelivaptan's preclinical paper is one of the most-cited pieces of evidence that vasopressin, not just oxytocin, plays a direct role in stress and anxiety behavior.
Mechanism
Selective, orally active of the vasopressin V1b receptor, with additional antagonism at the oxytocin receptor; V1b blockade was intended to blunt HPA-axis and stress-hormone hyperactivity implicated in anxiety and depression.
Safetyrisks and cautions, not medical advice
Four placebo-controlled trials, each eight weeks long and each carrying an active antidepressant comparator, put patients on 100 mg or 250 mg twice daily, and the published account reports no tolerability finding of the kind that stops a programme. A separate four-week study looked specifically at the stress-hormone axis and found no harmful effect on it, which mattered because that axis was the drug's whole target. Development ended in 2008 on efficacy grounds. The human record therefore runs to two months and no further, with nothing on long-term vasopressin blockade.
History
Developed by Sanofi-Aventis; preclinical work published in 2002 showed anxiolytic- and antidepressant-like effects in rodents. Four randomized, double-blind, placebo-controlled Phase II trials in MDD and GAD ran from August 2006 through February 2008, after which the program was discontinued for lack of clinical efficacy.
Subjective profileweighing the evidence above
A mechanistically bold experiment that proved the vasopressin V1b hypothesis does not translate cleanly from rodent stress models to human anxiety and depression.
Resources
This entry is here for reference.
Research
- 1.The vasopressin V1b receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies
- 2.Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders
2 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Did nelivaptan work for anxiety in humans?
No. Across four large placebo-controlled trials it failed to show meaningful benefit for generalized anxiety disorder despite strong preclinical rodent data.
What made nelivaptan mechanistically different from other anxiolytics?
It targeted the vasopressin V1b receptor, part of the body's stress-hormone axis, instead of serotonin or GABA-A, the targets of SSRIs and benzodiazepines.
Limitations of the evidence
- no meaningful efficacy signal over placebo in the human GAD trials
- inconsistent, unconvincing signal in the depression trials